NBNaveen Bangia

Naveen Bangia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Naveen Bangia has a total of 103 co-authors. Here are the top co-authors by number of shared publications:

  • Jennifer Blickwedehl

    Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York, USA

    5 shared publications
  • Peter Cresswell

    Section of Immunobiology, Yale University School of Medicine, New Haven, CT, 06520

    5 shared publications
  • Sarah McEvoy

    Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, 14263

    4 shared publications
  • Alan Belicha-Villanueva

    Immunology, and

    3 shared publications
  • Gundo Diedrich

    Section of Immunobiology, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06510, USA

    3 shared publications
  • Sandra O. Gollnick

    Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, 14263

    3 shared publications

Latest Publications

  • The Proteasome Activator PA200 Regulates Tumor Cell Responsiveness to Glutamine and Resistance to Ionizing Radiation

    by Jennifer Blickwedehl, Scott Olejniczak, Ryan Cummings, Nilofar Sarvaiya, Ana Mantilla, Asher Chanan-Khan, Tej K. Pandita, Marion Schmidt, Craig B. Thompson, Naveen Bangia

    The cellular response to ionizing radiation (IR) involves a variety of mechanisms to repair damage and maintain cell survival. We previously reported that the proteasome activator PA200 promotes long-term cell survival after IR exposure. The molecular function of PA200 is to enhance proteasome-mediated cleavage after glutamate; however, it is not known how this molecular function promotes survival after IR exposure. Here, we report that upon IR exposure, cellular demand for exogenous glutamine is increased. Cells containing PA200 are capable of surviving this IR-induced glutamine demand, whereas PA200-deficient cells show impaired long-term survival. Additional glutamine supplementation reverses the radiosensitivity of PA200-knockdown cells suggesting impaired glutamine homeostasis in these cells. Indeed, PA200-knockdown cells are unable to maintain intracellular glutamine levels. Furthermore, when extracellular glutamine is limiting, cells that contain PA200 respond by slowing growth, but PA200-knockdown cells and cells in which post-glutamyl proteasome activity is inhibited are nonresponsive and continue rapid growth. This cellular unresponsiveness to nutrient depletion is also reflected at the level of the mTOR substrate ribosomal S6 kinase (S6K). Thus, inability to restrict growth causes PA200-deficient cells to continue growing and eventually die due to lack of available glutamine. Together, these data indicate an important role for PA200 and post-glutamyl proteasome activity in maintaining glutamine homeostasis, which appears to be especially important for long-term survival of tumor cells after radiation exposure. Mol Cancer Res; 10(7); 937–44. ©2012 AACR.


  • Open Access

    Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma

    by Ping-Chiao Tsai, Francisco J. Hernandez-Ilizaliturri, Naveen Bangia, Scott H. Olejniczak, Myron S. Czuczman

    Purpose: The aim of this research was to further investigate the contribution of CD20 antigen expression to rituximab activity and define the mechanisms responsible for CD20 downregulation in rituximab-resistant cell lines (RRCL). Experimental Design: Rituximab-sensitive cell lines, RRCL, and primary neoplastic B cells were evaluated by chromium-51 release assays, ImageStream image analysis, immunohistochemical staining, flow cytometric analysis, CD20 knockdown, promoter activity, chromatin immunoprecipitation (ChIP) analysis of CD20 promoter, and CD20 plasmid transfection experiments to identify mechanisms associated with CD20 regulation in RRCL. Results: RRCL exhibited a gradual loss of CD20 surface expression with repeated exposure to rituximab. We identified a CD20 antigen surface threshold level required for effective rituximab-associated complement-mediated cytotoxicity (CMC). However, a direct correlation between CD20 surface expression and rituximab-CMC was observed only in rituximab-sensitive cell lines. CD20 promoter activity was decreased in RRCL. Detailed analysis of various CD20 promoter fragments suggested a lack of positive regulatory factors in RRCL. ChIP analysis showed reduced binding of several key positive regulatory proteins on CD20 promoter in RRCL. Interleukin-4 (IL-4) induced higher CD20 promoter activity and CD20 expression but modestly improved rituximab activity in RRCL and in primary B-cell lymphoma cells. Forced CD20 expression restored cytoplasmic but not surface CD20, suggesting the existence of a defect in CD20 protein transport in RRCL. Conclusions: We identified several mechanisms that alter CD20 expression in RRCL and showed that, whereas CD20 expression is important for rituximab activity, additional factors likely contribute to rituximab sensitivity in B-cell lymphoma. Clin Cancer Res; 18(4); 1039–50. ©2012 AACR.


  • The effect of photodynamic therapy on tumor cell expression of major histocompatibility complex (MHC) class I and MHC class I‐related molecules

    by Alan Belicha‐Villanueva, Jonah Riddell, Naveen Bangia, Sandra O. Gollnick

    Background and Objective: Photodynamic therapy (PDT) is FDA‐approved anti‐cancer modality for elimination of early disease and palliation in advanced disease. PDT efficacy depends in part on elicitation of a tumor‐specific immune response that is dependent on cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. The cytolytic potential of CTLs and NK cells is mediated by the ability of these cells to recognize major histocompatibility complex (MHC) class I and MHC class I‐related molecules. The MHC class I‐related molecules MICA and MICB are induced by oxidative stress and have been reported to activate NK cells and co‐stimulate CD8+ T cells. The purpose of this study was to examine the effect of PDT on tumor cell expression of MHC classes I and II‐related molecules in vivo and in vitro.Study Design/Materials and Methods: Human colon carcinoma Colo205 cells and murine CT26 tumors were treated with 2‐[1‐hexyloxyethyl]‐2‐devinyl pyropheophorbide‐a (HPPH)‐PDT at various doses. MHC classes I and I‐related molecule expression following treatment of Colo205 cells was temporally examined by flow cytometry using antibodies specific for components of MHC class I molecules and by quantitative PCR using specific primers. Expression of MHC class I‐related molecules following HPPH‐based PDT (HPPH‐PDT) of murine tumors was monitored using a chimeric NKG2D receptor.Results: In vitro HPPH‐PDT significantly induces MICA in Colo205 cells, but had no effect on MHC class I molecule expression. PDT also induced expression of NKG2D ligands (NKG2DL) following in vivo HPPH‐PDT of a murine tumor. Induction of MICA corresponded to increased NK killing of PDT‐treated tumor cells.Conclusions: PDT induction of MICA on human tumor cells and increased expression of NKG2DL by murine tumors following PDT may play a role in PDT induction of anti‐tumor immunity. This conclusion is supported by our results demonstrating that tumor cells have increased sensitivity to NK cell lysis following PDT. Lasers Surg. Med. 44:60–68, 2012.


  • Open Access

    Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response

    by Asher A. Chanan‐Khan, Kasyapa Chitta, Noreen Ersing, Aneel Paulus, Aisha Masood, Taimur Sher, Abhisek Swaika, Paul K. Wallace, Terry L. Mashtare, Greg Wilding, et al.

    Summary: Lenalidomide has demonstrated impressive antileukaemic effects in patients with chronic lymphocytic leukaemia (CLL). The mechanism(s) by which it mediates these effects remain unclear. Clinically, CLL patients treated with lenalidomide demonstrate an acute inflammatory reaction, the tumour flare reaction that is suggestive of an immune activation phenomenon. Samples from CLL patients treated with lenalidomide were used to evaluate its effect on the tumour cell and components of its microenvironment (immune cellular and cytokine). Lenalidomide was unable to directly induce apoptosis in CLL cells in vitro, however it modulated costimulatory (CD80, CD83, CD86) surface molecules on CLL cells in vitro and in vivo. Concurrently, we demonstrated that NK cell proliferation was induced by lenalidomide treatment in patients and correlated with clinical response. Cytokine analysis showed increase in levels of TNF‐α post‐lenalidomide treatment, consistent with acute inflammatory reaction. Furthermore, the basal cytokine profile (high IL‐8, MIG, IP‐10 and IL‐4 levels and low IL‐5, MIP1a, MIP1b, IL12/p70) was predictive of clinical response to lenalidomide. Collectively, our correlative studies provide further evidence that the antileukaemic effect of lenalidomide in CLL is mediated not only through modulation of the leukaemic clone but also through elements of the tumour microenvironment.


  • Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells

    by Scott H. Olejniczak, Jennifer Blickwedehl, Alan Belicha-Villanueva, Naveen Bangia, Wasif Riaz, Cory Mavis, James L. Clements, John Gibbs, Francisco J. Hernandez-Ilizaliturri, Myron S. Czuczman

    Resistance to currently available therapies is a major impediment to the successful treatment of hematological malignancies. Here, we used a model of therapy-resistant B-cell nonHodgkin lymphoma (B-NHL) developed in our laboratory along with primary B-NHL cells to study basic mechanisms of bortezomib activity. In resistant cells and a subset of primary B-NHLs, bortezomib treatment led to stabilization of Bak and subsequent Bak-dependent activation of apoptosis. In contrast to sensitive cells that die strictly by apoptosis, bortezomib was capable of killing resistant cells through activation of apoptosis or caspase-independent mechanism(s) when caspases were pharmacologically inhibited. Our data demonstrate that bortezomib is capable of killing B-NHL cells via multiple mechanisms, regardless of their basal apoptotic potential, and contributes to growing evidence that proteasome inhibitors can act via modulation of B-cell lymphoma 2 (Bcl-2) family proteins. The capacity of bortezomib to act independently of the intrinsic apoptotic threshold of a given B-NHL cell suggests that bortezomib-based therapies could potentially overcome resistance and result in relevant clinical activity in a relapsed/refractory setting.


  • Identification of an alternate splice form of tapasin in human melanoma

    by Alan Belicha-Villanueva, Michelle Golding, Sarah McEvoy, Nilofar Sarvaiya, Peter Cresswell, Sandra O. Gollnick, Naveen Bangia


  • Assembly and intracellular trafficking of HLA-B*3501 and HLA-B*3503

    by Vilasack Thammavongsa, Malinda Schaefer, Tracey Filzen, Kathleen L. Collins, Mary Carrington, Naveen Bangia, Malini Raghavan

    Residue 116 of major histocompatibility complex (MHC) class I heavy chains is an important determinant of assembly, that can influence rates of ER-Golgi trafficking, binding to the transporter associated with antigen processing (TAP), tapasin dependence of assembly, and the efficiency and specificity of peptide binding. Here, we investigated assembly and peptide-binding differences between HLA-B*3501(S116) and HLA-B*3503(F116), two alleles differing only at position 116 of the MHC class I heavy chain, that are associated respectively with normal or rapid AIDS progression. A reduced intracellular maturation rate was observed for HLA-B*3503 in HIV-infected and uninfected cells, which correlated with enhanced binding of HLA-B*3503 to TAP. No significant differences in the intrinsic efficiency of in vitro peptide binding by HLA-B*3501 and HLA-B*3503 were measurable with several common peptides or peptide libraries, and both allotypes were relatively tapasin-independent for their assembly. However, thermostability differences between the two allotypes were measurable in a CD4+ T cell line. These findings suggest that compared to HLA-B*3501, a reduced intracellular peptide repertoire for HLA-B*3503 could contribute to its slower intracellular trafficking and stronger association with rapid AIDS progression.


  • What is the role of alternate splicing in antigen presentation by major histocompatibility complex class I molecules?

    by Alan Belicha-Villanueva, Jennifer Blickwedehl, Sarah McEvoy, Michelle Golding, Sandra O. Gollnick, Naveen Bangia

    The expression of major histocompatibility complex (MHC) class I molecules on the cell surface is critical for recognition by cytotoxic T lymphocytes (CTL). This recognition event leads to destruction of cells displaying MHC class I—viral peptide complexes or cells displaying MHC class I—mutant peptide complexes. Before they can be transported to the cell surface, MHC class I molecules must associate with their peptide ligand in the endoplasmic reticulum (ER) of the cell. Within the ER, numerous proteins assist in the appropriate assembly and folding of MHC class I molecules. These include the heterodimeric transporter associated with antigen processing (TAP1 and TAP2), the heterodimeric chaperone-oxidoreductase complex of tapasin and ERp57 and the general ER chaperones calreticulin and calnexin. Each of these accessory proteins has a well-defined role in antigen presentation by MHC class I molecules. However, alternate splice forms of MHC class I heavy chains, TAP and tapasin, have been reported suggesting additional complexity to the picture of antigen presentation. Here, we review the importance of these different accessory proteins and the progress in our understanding of alternate splicing in antigen presentation.